{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:48:45Z","timestamp":1794646125099,"version":"4.9.1"},"reference-count":45,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DMSG OV D\u00fcsseldorf u.U.e.V.","award":["no grant number"],"award-info":[{"award-number":["no grant number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Vaccination has proven to be effective in preventing SARS-CoV-2 transmission and severe disease courses. However, immunocompromised patients have not been included in clinical trials and real-world clinical data point to an attenuated immune response to SARS-CoV-2 vaccines among patients with multiple sclerosis (MS) receiving immunomodulatory therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective study including 59 ocrelizumab (OCR)-treated patients with MS who received SARS-CoV-2 vaccination. Anti-SARS-CoV-2-antibody titres, routine blood parameters and peripheral immune cell profiles were measured prior to the first (baseline) and at a median of 4\u2009weeks after the second vaccine dose (follow-up). Moreover, the SARS-CoV-2-specific T cell response and peripheral B cell subsets were analysed at follow-up. Finally, vaccination-related adverse events were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After vaccination, we found anti-SARS-CoV-2(S) antibodies in 27.1% and a SARS-CoV-2-specific T cell response in 92.7% of MS cases. T cell-mediated interferon (IFN)-\u03b3 release was more pronounced in patients without anti-SARS-CoV-2(S) antibodies. Antibody titres positively correlated with peripheral B cell counts, time since last infusion and total IgM levels. They negatively correlated with the number of previous infusion cycles. Peripheral plasma cells were increased in antibody-positive patients. A positive correlation between T cell response and peripheral lymphocyte counts was observed. Moreover, IFN-\u03b3 release was negatively correlated with the time since the last infusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In OCR-treated patients with MS, the humoral immune response to SARS-CoV-2 vaccination is attenuated while the T cell response is preserved. However, it is still unclear whether T or B cell-mediated immunity is required for effective clinical protection. Nonetheless, given the long-lasting clinical effects of OCR, monitoring of peripheral B cell counts could facilitate individualised treatment regimens and might be used to identify the optimal time to vaccinate.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2021-328197","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T18:25:59Z","timestamp":1645554359000},"page":"978-985","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab"],"prefix":"10.1136","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-5572","authenticated-orcid":false,"given":"Saskia","family":"R\u00e4uber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Korsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Huntemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leoni","family":"Rolfes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00fcntefering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Dobelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"K\u00f6lsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"von Wnuck Lipinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-7143","authenticated-orcid":false,"given":"Christopher","family":"Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesa","family":"Regner-Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ingwersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Teegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-8864","authenticated-orcid":false,"given":"Michael Harry","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7987-658X","authenticated-orcid":false,"given":"Philipp","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodo","family":"Levkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-9907","authenticated-orcid":false,"given":"David","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"2023051801202595000_93.9.978.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2023051801202595000_93.9.978.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2023051801202595000_93.9.978.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0485-4"},{"key":"2023051801202595000_93.9.978.4","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02059-5"},{"key":"2023051801202595000_93.9.978.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906"},{"key":"2023051801202595000_93.9.978.6","unstructured":"European Medicines Agency . Ocrevus - Summary of product characteristics [Internet]. Available: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20210111150165\/anx_150165_en.pdf [Accessed 15 Jun 2021]."},{"key":"2023051801202595000_93.9.978.7","unstructured":"Roche H-L . New data for Roche\u2019s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis [Internet]. Available: https:\/\/www.roche.com\/media\/releases\/med-cor-2021-04-16.htm [Accessed 06 Oct 2021]."},{"key":"2023051801202595000_93.9.978.8","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15 Suppl 1","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2023051801202595000_93.9.978.9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.humimm.2019.01.001","article-title":"CD3+CD20+ T cells and their roles in human diseases","volume":"80","author":"Chen","year":"2019","journal-title":"Hum Immunol"},{"key":"2023051801202595000_93.9.978.10","doi-asserted-by":"publisher","DOI":"10.1038\/nri3857"},{"key":"2023051801202595000_93.9.978.11","doi-asserted-by":"publisher","DOI":"10.1038\/nri3795"},{"key":"2023051801202595000_93.9.978.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01507-2"},{"key":"2023051801202595000_93.9.978.13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-326839"},{"key":"2023051801202595000_93.9.978.14","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.3599","article-title":"Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with Ocrelizumab","volume":"78","author":"Brill","year":"2021","journal-title":"JAMA Neurol"},{"key":"2023051801202595000_93.9.978.15","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.3609","article-title":"Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis","volume":"78","author":"Disanto","year":"2021","journal-title":"JAMA Neurol"},{"key":"2023051801202595000_93.9.978.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"2023051801202595000_93.9.978.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"2023051801202595000_93.9.978.18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s42003-020-01526-8","article-title":"The kinetics of humoral response and its relationship with the disease severity in COVID-19","volume":"3","author":"Ren","year":"2020","journal-title":"Commun Biol"},{"key":"2023051801202595000_93.9.978.19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"2023051801202595000_93.9.978.20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmsb2104756"},{"key":"2023051801202595000_93.9.978.21","doi-asserted-by":"crossref","unstructured":"Ferguson J , Murugesan K , Banaei N . Interferon-Gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report. Int J Infect Dis 2021.","DOI":"10.1016\/j.ijid.2021.06.054"},{"key":"2023051801202595000_93.9.978.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2023051801202595000_93.9.978.23","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023051801202595000_93.9.978.24","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1002\/jmv.27098","article-title":"Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers","volume":"93","author":"Bayram","year":"2021","journal-title":"J Med Virol"},{"key":"2023051801202595000_93.9.978.25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149335","article-title":"SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63","volume":"131","author":"Woldemeskel","year":"2021","journal-title":"J Clin Invest"},{"key":"2023051801202595000_93.9.978.26","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26028"},{"key":"2023051801202595000_93.9.978.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102472"},{"key":"2023051801202595000_93.9.978.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102195"},{"key":"2023051801202595000_93.9.978.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102185"},{"key":"2023051801202595000_93.9.978.30","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS: observational study of early experience from NYU multiple sclerosis comprehensive care center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023051801202595000_93.9.978.31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol"},{"key":"2023051801202595000_93.9.978.32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013108"},{"key":"2023051801202595000_93.9.978.33","doi-asserted-by":"crossref","unstructured":"Achiron A , Mandel M , Dreyer-Alster S , et al . Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 2021;14:17562864211012836.doi:10.1177\/17562864211012835","DOI":"10.1177\/17562864211012835"},{"key":"2023051801202595000_93.9.978.34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and opportunities for consistent classification of human B cell and plasma cell populations","volume":"10","author":"Sanz","year":"2019","journal-title":"Front Immunol"},{"key":"2023051801202595000_93.9.978.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.22019"},{"key":"2023051801202595000_93.9.978.36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1756285616666741","article-title":"Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management","volume":"10","author":"Bittner","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"2023051801202595000_93.9.978.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2550-z"},{"key":"2023051801202595000_93.9.978.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc070348"},{"key":"2023051801202595000_93.9.978.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.02.063"},{"key":"2023051801202595000_93.9.978.40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137799","article-title":"The laboratory tests and host immunity of COVID-19 patients with different severity of illness","volume":"5","author":"Wang","year":"2020","journal-title":"JCI Insight"},{"key":"2023051801202595000_93.9.978.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.12.011"},{"key":"2023051801202595000_93.9.978.42","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00024-07"},{"key":"2023051801202595000_93.9.978.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.06.001"},{"key":"2023051801202595000_93.9.978.44","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1111\/ene.15028","article-title":"Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): early experience from a tertiary MS center in Israel","volume":"28","author":"Lotan","year":"2021","journal-title":"Eur J Neurol"},{"key":"2023051801202595000_93.9.978.45","doi-asserted-by":"crossref","unstructured":"Di Filippo M , Cordioli C , Malucchi S . mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatr 2021.","DOI":"10.1136\/jnnp-2021-327200"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2021-328197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:24:40Z","timestamp":1684398280000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2021-328197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,8,12]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/jnnp-2021-328197"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2021-328197","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}